Literature DB >> 6661359

Acute treatment of hypertensive crisis with nifedipine.

F T Huysmans, H E Sluiter, T A Thien, R A Koene.   

Abstract

Ten patients with a hypertensive crisis and a decreased renal function were treated with 10 (n = 7) or 20 (n = 3) mg nifedipine sublingually. Blood pressure was reduced in 60 min from 211 +/- 4/134 +/- 5 to 172 +/- 6/107 +/- 6 mm Hg. The decrease of blood pressure was accompanied by a rise in heart rate from 83 +/- 6 to 98 +/- 5 beats/min. In all seven patients with an encephalopathy signs of this complication were reduced. No serious side-effects were observed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6661359      PMCID: PMC1428348          DOI: 10.1111/j.1365-2125.1983.tb02250.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  A point-score system for the ECG diagnosis of left ventricular hypertrophy.

Authors:  D W Romhilt; E H Estes
Journal:  Am Heart J       Date:  1968-06       Impact factor: 4.749

2.  Antihypertensive effect of (4-2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonic acid dimethylester (Nifedipine, Bay-a 1040), a new coronary dilator.

Authors:  M Murakami; E Murakami; N Takekoshi; M Tsuchiya; T Kin
Journal:  Jpn Heart J       Date:  1972-03

3.  Antihypertensive effect of nifedipine and its relationship to severity of hypertension.

Authors:  M Yoshimura; R Takashina; R Shikuma; H Takahashi; K Takeda; H Ashizawa; Y Ochi; H Ijichi
Journal:  Arzneimittelforschung       Date:  1983

4.  The effects of calcium channel blocking agents on cardiovascular function.

Authors:  R I Low; P Takeda; D T Mason; A N DeMaria
Journal:  Am J Cardiol       Date:  1982-02-18       Impact factor: 2.778

5.  Differential cardiovascular effects of calcium channel blocking agents: potential mechanisms.

Authors:  R W Millard; D A Lathrop; G Grupp; M Ashraf; I L Grupp; A Schwartz
Journal:  Am J Cardiol       Date:  1982-02-18       Impact factor: 2.778

6.  Nifedipine in hypertensive emergencies.

Authors:  O Bertel; D Conen; E W Radü; J Müller; C Lang; U C Dubach
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-01

7.  Nifedipine in the treatment of hypertension: report of a double-blind controlled trial.

Authors:  S Bayley; R J Dobbs; B F Robinson
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

  7 in total
  8 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 2.  Hypertensive emergencies and urgencies: definition, recognition, and management.

Authors:  J B Reuler; G J Magarian
Journal:  J Gen Intern Med       Date:  1988 Jan-Feb       Impact factor: 5.128

Review 3.  Comparative tolerability profile of hypertensive crisis treatments.

Authors:  E Grossman; A N Ironi; F H Messerli
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

4.  Treatment of hypertensive emergency. Comparison of a new dosage form of the calcium antagonist nitrendipine with nifedipine capsules.

Authors:  G Rohr; P Reimnitz; P Blanke
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

Review 5.  Treatment of severe hypertension and hypertensive crises with nifedipine.

Authors:  M C Houston
Journal:  West J Med       Date:  1987-06

Review 6.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 7.  Treatment of acute severe hypertension: current and newer agents.

Authors:  Joseph Varon
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Clinical review: the management of hypertensive crises.

Authors:  Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2003-07-16       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.